S&P 500   4,314.89 (-0.81%)
DOW   34,062.51 (-0.31%)
QQQ   341.73 (-0.82%)
AAPL   159.36 (-0.21%)
MSFT   299.23 (+0.85%)
FB   295.98 (+0.46%)
GOOGL   2,584.23 (-0.02%)
AMZN   2,796.64 (+0.69%)
TSLA   842.33 (-10.14%)
NVDA   220.36 (-3.23%)
BABA   112.21 (-1.02%)
NIO   21.24 (-6.27%)
AMD   103.51 (-6.50%)
CGC   6.88 (-4.84%)
MU   78.91 (-3.73%)
GE   89.58 (+0.29%)
T   24.21 (-0.16%)
F   19.70 (-1.05%)
DIS   135.89 (+1.71%)
AMC   14.65 (-8.09%)
PFE   53.73 (+1.36%)
ACB   3.82 (-5.91%)
BA   190.17 (-2.11%)
S&P 500   4,314.89 (-0.81%)
DOW   34,062.51 (-0.31%)
QQQ   341.73 (-0.82%)
AAPL   159.36 (-0.21%)
MSFT   299.23 (+0.85%)
FB   295.98 (+0.46%)
GOOGL   2,584.23 (-0.02%)
AMZN   2,796.64 (+0.69%)
TSLA   842.33 (-10.14%)
NVDA   220.36 (-3.23%)
BABA   112.21 (-1.02%)
NIO   21.24 (-6.27%)
AMD   103.51 (-6.50%)
CGC   6.88 (-4.84%)
MU   78.91 (-3.73%)
GE   89.58 (+0.29%)
T   24.21 (-0.16%)
F   19.70 (-1.05%)
DIS   135.89 (+1.71%)
AMC   14.65 (-8.09%)
PFE   53.73 (+1.36%)
ACB   3.82 (-5.91%)
BA   190.17 (-2.11%)
S&P 500   4,314.89 (-0.81%)
DOW   34,062.51 (-0.31%)
QQQ   341.73 (-0.82%)
AAPL   159.36 (-0.21%)
MSFT   299.23 (+0.85%)
FB   295.98 (+0.46%)
GOOGL   2,584.23 (-0.02%)
AMZN   2,796.64 (+0.69%)
TSLA   842.33 (-10.14%)
NVDA   220.36 (-3.23%)
BABA   112.21 (-1.02%)
NIO   21.24 (-6.27%)
AMD   103.51 (-6.50%)
CGC   6.88 (-4.84%)
MU   78.91 (-3.73%)
GE   89.58 (+0.29%)
T   24.21 (-0.16%)
F   19.70 (-1.05%)
DIS   135.89 (+1.71%)
AMC   14.65 (-8.09%)
PFE   53.73 (+1.36%)
ACB   3.82 (-5.91%)
BA   190.17 (-2.11%)
S&P 500   4,314.89 (-0.81%)
DOW   34,062.51 (-0.31%)
QQQ   341.73 (-0.82%)
AAPL   159.36 (-0.21%)
MSFT   299.23 (+0.85%)
FB   295.98 (+0.46%)
GOOGL   2,584.23 (-0.02%)
AMZN   2,796.64 (+0.69%)
TSLA   842.33 (-10.14%)
NVDA   220.36 (-3.23%)
BABA   112.21 (-1.02%)
NIO   21.24 (-6.27%)
AMD   103.51 (-6.50%)
CGC   6.88 (-4.84%)
MU   78.91 (-3.73%)
GE   89.58 (+0.29%)
T   24.21 (-0.16%)
F   19.70 (-1.05%)
DIS   135.89 (+1.71%)
AMC   14.65 (-8.09%)
PFE   53.73 (+1.36%)
ACB   3.82 (-5.91%)
BA   190.17 (-2.11%)
NASDAQ:ANGO

AngioDynamics Stock Forecast, Price & News

$20.30
-0.98 (-4.61%)
(As of 01/27/2022 03:08 PM ET)
Add
Compare
Today's Range
$20.22
$21.65
50-Day Range
$21.28
$29.16
52-Week Range
$18.29
$32.00
Volume
15,928 shs
Average Volume
529,159 shs
Market Capitalization
$785.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.89
30 days | 90 days | 365 days | Advanced Chart
Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.


AngioDynamics logo

About AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Headlines

Where Do Hedge Funds Stand On AngioDynamics, Inc. (ANGO)?
January 12, 2022 |  finance.yahoo.com
AngioDynamics (NASDAQ:ANGO) Shares Down 5.8%
January 7, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ANGO
CUSIP
03475V10
Employees
800
Year Founded
1988

Sales & Book Value

Annual Sales
$291.01 million
Cash Flow
$0.66 per share
Book Value
$11.17 per share

Profitability

Net Income
$-31.55 million
Pretax Margin
-14.36%

Debt

Price-To-Earnings

Miscellaneous

Free Float
36,859,000
Market Cap
$785.96 million
Optionable
Optionable

Company Calendar

Last Earnings
1/05/2022
Today
1/27/2022
Next Earnings (Estimated)
3/29/2022
Fiscal Year End
5/31/2022

Social Links


MarketRank

Overall MarketRank

2.32 out of 5 stars

Medical Sector

269th out of 1,419 stocks

Surgical & Medical Instruments Industry

31st out of 130 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

Is AngioDynamics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AngioDynamics stock.
View analyst ratings for AngioDynamics
or view top-rated stocks.

How has AngioDynamics' stock price been impacted by COVID-19?

AngioDynamics' stock was trading at $10.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ANGO stock has increased by 100.6% and is now trading at $20.34.
View which stocks have been most impacted by COVID-19
.

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for AngioDynamics
.

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings data on Wednesday, January, 5th. The medical instruments supplier reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.03. The medical instruments supplier earned $78.30 million during the quarter, compared to analyst estimates of $77.90 million. AngioDynamics had a negative trailing twelve-month return on equity of 0.24% and a negative net margin of 12.64%. The business's revenue for the quarter was up 7.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.01 EPS.
View AngioDynamics' earnings history
.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics updated its FY22 earnings guidance on Thursday, January, 6th. The company provided EPS guidance of ($0.02) -$0.02 for the period, compared to the Thomson Reuters consensus estimate of $0.02. The company issued revenue guidance of $310-315 million, compared to the consensus revenue estimate of $313.70 million.

What price target have analysts set for ANGO?

2 Wall Street analysts have issued 12-month price targets for AngioDynamics' shares. Their forecasts range from $32.00 to $32.00. On average, they anticipate AngioDynamics' share price to reach $32.00 in the next year. This suggests a possible upside of 57.3% from the stock's current price.
View analysts' price targets for AngioDynamics
or view top-rated stocks among Wall Street analysts.

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the following people:
  • James Christopher Clemmer, President, Chief Executive Officer & Director
  • David D. Helsel, SVP-Global Operations, Research & Development (LinkedIn Profile)
  • Stephen A. Trowbridge, Chief Financial Officer & Executive Vice President
  • Kim L. Seabury, Senior Vice President-Information Technology
  • Juan Carlos Serna, Senior VP-Scientific & Clinical Affairs

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

27 employees have rated AngioDynamics CEO James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among AngioDynamics' employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.58%), Strs Ohio (0.09%), State of Alaska Department of Revenue (0.07%), Russell Investments Group Ltd. (0.05%), Diversified Trust Co (0.03%) and Concord Wealth Partners (0.01%). Company insiders that own AngioDynamics stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends for AngioDynamics
.

Which institutional investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Frontier Capital Management Co. LLC, and State of Alaska Department of Revenue. Company insiders that have sold AngioDynamics company stock in the last year include Chad Thomas Campbell, Dave Helsel, and Scott Centea.
View insider buying and selling activity for AngioDynamics
or view top insider-selling stocks.

Which institutional investors are buying AngioDynamics stock?

ANGO stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co, Strs Ohio, and Concord Wealth Partners. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer, and Stephen A Trowbridge.
View insider buying and selling activity for AngioDynamics
or or view top insider-buying stocks.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $20.34.

How much money does AngioDynamics make?

AngioDynamics has a market capitalization of $787.50 million and generates $291.01 million in revenue each year. The medical instruments supplier earns $-31.55 million in net income (profit) each year or ($0.99) on an earnings per share basis.

How many employees does AngioDynamics have?

AngioDynamics employs 800 workers across the globe.

Does AngioDynamics have any subsidiaries?

The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.

When was AngioDynamics founded?

AngioDynamics was founded in 1988.

What is AngioDynamics' official website?

The official website for AngioDynamics is www.angiodynamics.com.

Where are AngioDynamics' headquarters?

AngioDynamics is headquartered at 14 PLAZA DRIVE, LATHAM NY, 12110.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at [email protected], or via fax at 518-795-1401.


This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.